DOCSLIB.ORG

PRODUCT CATALOGUE 2021 Available on Product Known Teva Tech US EU Japan Korea Therapeutic Api IP file*** DMF DMF DMF DMF Area**

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PRODUCT CATALOGUE 2021 Available on Product Known Teva Tech US EU Japan Korea Therapeutic Api IP file*** DMF DMF DMF DMF Area** S NH2 N N O O O HN CH OH 3 N O SO3H PRODUCT CATALOGUE 2021 Available on www.teva-api.com Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** A ABALOPARATIDE Osteoporosis ABEMACICLIB Oncology ABIRATERONE ACETATE Oncology ACALABRUTINIB Oncology AFATINIB Oncology ALCLOMETASONE DIPROPIONATE Dermatology ALLOPURINOL Rheumatology CEP AMCINONIDE Dermatology AMITRIPTYLINE HCl Neurology - Psychiatry CEP ANASTROZOLE Oncology CEP ANIDULAFUNGIN Infectious disease APALUTAMIDE* Oncology Coagulation APIXABAN inhibitors APREMILAST* Psoriasis ARIPIPRAZOLE* Neurology-Psychiatry CEP ATOMOXETINE HCl Neurology-Psychiatry ATORVASTATIN CALCIUM Lipid lowering CEP Preterm labor ATOSIBAN ACETATE prevention ATRACURIUM BESYLATE Muscle relaxant CEP AZACITIDINE Oncology AZITHROMYCIN DIHYDRATE Infectious disease CEP AZITHROMYCIN MONOHYDRATE Infectious disease CEP AZTREONAM* Infectious disease B BALOXAVIR Antiviral 2 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** BARICITINIB Rheumatology BECLOMETHASONE DIPROPIONATE Respiratory CEP BETAMETHASONE ACETATE Inflammation BETAMETHASONE BASE Dermatology CEP BETAMETHASONE DIPROPIONATE Dermatology CEP BETAMETHASONE VALERATE Dermatology CEP BICALUTAMIDE Oncology CEP BIVALIRUDIN Hematology BLEOMYCIN SULFATE Oncology BORTEZOMIB Oncology BREXANOLONE Neurology-Psychiatry BREXPIPRAZOLE Neurology-Psychiatry BROMOCRIPTINE MESYLATE Cardiovascular CEP BUDESONIDE Respiratory CEP BUPRENORPHINE BASE Neurology-Psychiatry CEP BUPRENORPHINE HCl Neurology-Psychiatry CEP BUTORPHANOL TARTRATE Analgesic C CABAZITAXEL Oncology Prolactinoma CABERGOLINE treatment CEP CALCIPOTRIENE* Immunology CEP Endocrinology CALCITRIOL & Metabolism CEP CANDESARTAN CILEXETIL Cardiovascular CEP CARBIDOPA Parkinson CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 3 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** CARBOPLATIN Oncology CEP CARFILZOMIB Oncology CARVEDILOL PHOSPHATE Cardiovascular CASPOFUNGIN ACETATE Infectious disease Endocrinology CHLORMADINONE ACETATE & Metabolism CICLOSPORINE Immunology CEP Coagulation CILOSTAZOL inhibitors Endocrinology CINACALCET HCl & Metabolism CISATRACURIUM BESYLATE Muscle relaxant CEP CISPLATIN Oncology CEP CLARITHROMYCIN Infectious disease CEP CLASCOTERONE Dermatology CLOBETASOL PROPIONATE Dermatology CEP Coagulation CLOPIDOGREL BISULFATE* inhibitors CEP CRISABOROLE Dermatology Endocrinology CYPROTERONE ACETATE & Metabolism CEP Coagulation D DABIGATRAN ETEXILATE inhibitors DALBAVANCIN Infectious disease DASATINIB* Oncology DAUNORUBICIN HCl Oncology CEP DEFERASIROX Hematology DEFEROXAMINE MESYLATE Hematology CEP DEPRODONE PROPIONATE Dermatology DESLORATADINE Allergology DESMOPRESSIN ACETATE Nocturia CEP 4 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** DESONIDE Dermatology DESOXYCORTICOSTERONE Immunology DESVENLAFAXINE BASE Neurology-Psychiatry DESVENLAFAXINE SUCCINATE Neurology-Psychiatry DEXAMETHASONE - 17 VALERATE Inflammation DEXRAZOXANE (ICRF) Cardiovascular DIAZOXIDE Cardiovascular DIFLORASONE DIACETATE Dermatology DIFLUPREDNATE Ophthalmology DIHYDROERGOTAMINE MESYLATE Migraine CEP DIHYDROERGOTOXINE MESYLATE Neurology-Psychiatry CEP DILTIAZEM HCl Cardiovascular CEP DIMETHYL FUMARATE Immunology DIROXIMEL FUMARATE Immunology DOCETAXEL Oncology DOCOSANOL Antiviral DONEPEZIL HCl* Neurology-Psychiatry DORZOLAMIDE HCl Ophthalmology CEP DOXEPIN HCl Neurology-Psychiatry CEP Endocrinology DOXERCALCIFEROL & Metabolism DOXORUBICIN HCl Oncology CEP Endocrinology DROSPIRENONE & Metabolism CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 5 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** Coagulation E EDOXABAN TOSYLATE inhibitors ELAGOLIX Genitourinary ELETRIPTAN HBr Migraine ELTROMBOPAG OLAMINE Hematology ELUXADOLINE Gastroenterology EMPAGLIFLOZIN Diabetes EPIRUBICIN HCl Oncology CEP EPTIFIBATIDE Hematology Postpartum ERGOMETRINE (ERGONOVINE) MALEATE haemorrhage CEP ERGOTAMINE TARTRATE Migraine CEP ERLOTINIB HCl* Oncology ESZOPICLONE Neurology-Psychiatry ETODOLAC Inflammation CEP ETOPOSIDE Oncology CEP EZETIMIBE Lipid lowering F FAMCICLOVIR Antiviral FEBUXOSTAT Rheumatology FINGOLIMOD HCl Immunology CEP FLUDARABINE PHOSPHATE Oncology CEP FLUDROCORTISONE ACETATE Genitourinary FLUNISOLIDE* Respiratory FLUOCINOLONE ACETONIDE* Dermatology FLUOCINONIDE* Dermatology FLUOROMETHOLONE ACETATE Ophthalmology FLUOROMETHOLONE BASE Ophthalmology 6 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** FLUOROURACIL - (5FU) Oncology CEP FLUOXETINE HCl Neurology-Psychiatry CEP FLUTICASONE FUROATE Respiratory FLUTICASONE PROPIONATE Respiratory CEP FLUVASTATIN SODIUM Lipid lowering CEP FORMOTEROL FUMARATE Respiratory CEP FULVESTRANT Oncology CEP FUROSEMIDE Cardiovascular CEP G GALANTAMINE HBr Neurology-Psychiatry CEP GEMCITABINE HCl Oncology CEP Endocrinology GLYCEROL PHENYLBUTYRATE & Metabolism H HALOPERIDOL Neurology-Psychiatry HALOPERIDOL DECANOATE Neurology-Psychiatry HYDROCHLOROTHIAZIDE* Cardiovascular CEP I IBRUTINIB Oncology ICATIBANT ACETATE Angioedema IDARUBICIN HCl Oncology IMATINIB MESYLATE* Oncology CEP IMIPRAMINE HCl Neurology-Psychiatry CEP IMIQUIMOD Dermatology IRBESARTAN Cardiovascular CEP IVOSIDENIB Oncology IXAZOMIB CITRATE Oncology * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 7 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** L LABETALOL HCl Cardiovascular CEP LAMOTRIGINE Epileptic CEP LANSOPRAZOLE Gastroenterology CEP LAROTRECTINIB Oncology LATANOPROSTENE BUNOD Ophthalmology LEDIPASVIR* Antiviral LETERMOVIR Antiviral LETROZOLE Oncology LEVOFLOXACIN Infectious disease LEVOSALBUTAMOL HCl (LEVALBUTEROL) Respiratory LIFITEGRAST Ophthalmology LINACLOTIDE Gastroenterology LINAGLIPTIN Diabetes LOPERAMIDE HCl Gastroenterology CEP LORLATINIB Oncology LOSARTAN POTASSIUM AZIDE Cardiovascular CEP LOVASTATIN Lipid lowering CEP LURASIDONE HCl Neurology-Psychiatry M MACITENTAN Cardiovascular Endocrinology MAXACALCITOL & Metabolism Endocrinology MEDROXYPROGESTERONE ACETATE & Metabolism CEP Endocrinology MEGESTROL ACETATE & Metabolism CEP MEMANTINE HCl Neurology-Psychiatry METHYLDOPA Cardiovascular CEP 8 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** Postpartum METHYLERGONOVINE MALEATE haemorrhage CEP METHYLPREDNISOLONE HEMISUCCINATE Inflammation METOPROLOL SUCCINATE Cardiovascular CEP METOPROLOL TARTRATE Cardiovascular CEP MICAFUNGIN SODIUM Infectious disease MIDOSTAURIN* Oncology MITOMYCIN Oncology CEP MOMETASONE FUROATE* Respiratory CEP MONTELUKAST SODIUM* Respiratory CEP MUPIROCIN* Infectious disease CEP MUPIROCIN CALCIUM Infectious disease CEP MYCOPHENOLATE MOFETIL Immunology CEP MYCOPHENOLATE SODIUM Immunology N NABUMETONE Inflammation CEP NERATINIB MALEATE Oncology NETARSUDIL MESYLATE Ophthalmology NICERGOLINE Cardiovascular CEP NIFEDIPINE Cardiovascular CEP NILOTINIB FUMARATE Oncology NILOTINIB HCl Oncology NILOTINIB TARTRATE Oncology NINTEDANIB ESYLATE Oncology NIRAPARIB TOSYLATE Oncology * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 9 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** NITROFURANTOIN* Infectious disease Endocrinology NOMEGESTROL ACETATE & Metabolism CEP Endocrinology NORGESTIMATE & Metabolism O OBETICHOLIC ACID Immunology Endocrinology OCTREOTIDE ACETATE & Metabolism OLANZAPINE Neurology - Psychiatry CEP OLMESARTAN MEDOXOMIL Cardiovascular CEP OLODATEROL HCl Respiratory OMEPRAZOLE Gastroenterology CEP ONDANSETRON BASE Gastroenterology ONDANSETRON HCl Gastroenterology CEP ORITAVANCIN Infectious disease OSIMERTINIB MESYLATE Oncology OXALIPLATIN Oncology CEP P PACLITAXEL Oncology CEP PALBOCICLIB Oncology PALIPERIDONE PALMITATE Neurology - Psychiatry PALONOSETRON HCl* Gastroenterology - Oncology PANCURONIUM BROMIDE Muscle relaxant CEP Endocrinology PARICALCITOL & Metabolism PEMETREXED* Oncology PERAMPANEL Epileptic PERGOLIDE MESYLATE Parkinson CEP PIOGLITAZONE HCl Diabetes PLECANATIDE Gastroenterology 10 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** PRALATREXATE
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • NG198 Evidence Review E1
    1 2 Research recommendations for review question: For people with mild to 3 moderate acne vulgaris what are the most effective treatment options? 4 Research question - physical modalities 5 What is the effectiveness of physical modalities (such as light devices) in the treatment of 6 acne vulgaris or persistent acne vulgaris-related scarring? 7 Why this is important 8 Physical treatments for acne are popular with people because they have the benefit of 9 treating a local area without systemic effects. They can be used in people with co-morbidities 10 or side effects where other treatments are unsuitable. They are currently available in the 11 private sector but there is no standardisation of treatment modalities or duration. Many 12 different physical therapies have been described for acne including: 13 • Comedone extraction 14 • Phototherapy – including UVB, intense pulsed light, blue and red light 15 • Photochemical therapy (e.g. photodynamic therapy) 16 • Laser 17 • Photopneumatic therapy (e.g. intense pulsed light + vacuum) 18 • Photothermal therapy (eg gold nanoparticles +light or laser) 19 Physical treatments are also used for acne scarring. These include: 20 • Punch excision 21 • CO2 laser 22 • Dermabrasion 23 • Radiofrequency (e.g. fractional microneedling, bipolar) 24 Further research is required to determine the most effective physical treatments for acne and 25 acne scarring. This could open the way to wider availability in the NHS. 26 Table 26: Research recommendation rationale Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Why is this needed Importance to ‘patients’ or the Physical treatments for acne are popular with people because population they have the benefit of treating a local area without systemic effects.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • June 2021 Therapeutic Research Center (TRC) Is the Leading Advisory Service on Drug Therapy and Medication Management
    June 2021 Therapeutic Research Center (TRC) is the leading advisory service on drug therapy and medication management. Every month over 400,000 prescribers, pharmacists, and pharmacy technicians rely on our unbiased, evidence-based clinical recommendations to help them improve medication use, prevent medication errors, and improve patient care and outcomes. We also have one of the most extensive CE/CME course offerings in the industry. Our accredited continuing education and continuing medical education courses are trusted and relied on by hundreds of thousands of pharmacists, technicians, and prescribers every month. Therapeutic Research Center does not receive commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Credit is reported to CPE Monitor, AAFP, and CE Broker as appropriate. Accreditation Information: Therapeutic Research Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians. Pharmacist’s Letter / Therapeutic Research Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Therapeutic Research Center / Prescriber’s Letter is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number:080517. Select Therapeutic Research Center courses are also acceptable for American Academy of Family Physicians (AAFP) Prescribed credit, American Osteopathic Association (AOA) credit, and American College of Emergency Physicians (ACEP) Category I Credit. Please refer to the detailed accreditation statements available online for each course. Get started at TherapeuticResearchCenter.com. Log in to access your course list or purchase a course or subscription. For additional assistance, please call 209-472-2240 and we’ll be happy to help you.
    [Show full text]
  • Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone
    Package leaflet: Information for the user ZYTIGA 500 mg film-coated tablets abiraterone acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What ZYTIGA is and what it is used for 2. What you need to know before you take ZYTIGA 3. How to take ZYTIGA 4. Possible side effects 5. How to store ZYTIGA 6. Contents of the pack and other information 1. What ZYTIGA is and what it is used for ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow the growth of prostate cancer. When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy ). When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Abiraterone Acetate for Chemotherapy-Naive
    Fan et al. BMC Urology (2018) 18:110 https://doi.org/10.1186/s12894-018-0416-6 RESEARCHARTICLE Open Access Abiraterone acetate for chemotherapy- naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Liancheng Fan†, Baijun Dong†, Chenfei Chi†, Yanqing Wang†, Yiming Gong†, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou* and Wei Xue* Abstract Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate- specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23. 3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively.
    [Show full text]
  • A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India
    OPEN ACCESS Freely available online e Journal of Pharmacovigilance ISSN: 2329-6887 Mini Review A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India ABSTRACT Uveitis is a moving illness to treat. Corticosteroids have been utilized in the treatment of uveitis for a long time. Immunosuppressives are acquiring force lately in the treatment of uveitis. In this article we present an outline of current treatment of uveitis and the significant discoveries and advances in medications and visual medication conveyance frameworks in the treatment of uveitis. Keywords: Corticosteroids; Immunosuppressives; Medical Management; Uveitis. INTRODUCTION prednisolone acetic acid derivation is multiple times less powerful on a molar premise than betamethasone or dexamethasone, the Uveitis is a potentially sight threatening disease. It may occur due entrance into the cornea of prednisolone acetic acid derivation is to an infection or may be due to an autoimmune etiology. Specific significantly more than betamethasone or dexamethasone. Dosing antimicrobial therapies with or without corticosteroids are used recurrence and the time span the medicine stays in contact with in cases of infectious uveitis. Several drugs are available for the visual surface additionally impacts adequacy. Suspensions have a management of non-infectious uveitis including corticosteroids, immunosuppressive agents, and more recently biologics. The more serious level of calming impact. treatment of uveitis is evolving
    [Show full text]
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]